DocMorris AG (DOCM) fair value: what the stock is really worth
We calculate from audited financials what DocMorris AG is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch DocMorris AG for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range CHF 3.98 – CHF 210.26 · fair‑value band CHF 1.02 – CHF 2.08 · the CHF 10.68 price screens above the CHF 1.65 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
DocMorris AG operates as an online pharmacy, telemedicine, and healthcare company in Switzerland and internationally. The company offers prescription and over-the-counter medicines, and consumer health products, as well as beauty and personal care products, nutritional supplements, painkillers, and first aid products.
Show more
DocMorris AG operates as an online pharmacy, telemedicine, and healthcare company in Switzerland and internationally. The company offers prescription and over-the-counter medicines, and consumer health products, as well as beauty and personal care products, nutritional supplements, painkillers, and first aid products. The company also provides professional health care services to doctors, pharmacies, insurers, and health institutions. It sells its products to online mail-order pharmacies, and private individuals under the DocMorris, PromoFarma by DocMorris, and TeleClinic brands. The company was formerly known as Zur Rose Group AG and changed its name to DocMorris AG in May 2023. DocMorris AG was founded in 1993 and is headquartered in Frauenfeld, Switzerland.
Stock analysis
DocMorris AG (DOCM) currently trades at CHF 10.68, while our model-based Fair Value estimate is CHF 1.65, implying the stock looks roughly 547.2% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of CHF 5.60 per share, and 0 of the 3 models we run sit above the CHF 10.68 price.
Bear case: the Dividend Discount group reads lowest at CHF 1.79, and 3 of the 3 models stay below the price. Evidence for this calculation is low.
Scenario range: CHF 1.02 (bear) to CHF 2.08 (bull), the price of CHF 10.68 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
DocMorris AG reported revenue of CHF 1.1B in FY2025 versus CHF 1.7B in FY2021, a compound −10.2%/yr. Reported net income was −CHF 134M in FY2025.
Key figures
Market cap CHF 551M · P/S ratio 0.30 · EPS (TTM) CHF −4.58 · Dividend yield 2.2% · Net margin −12.0% · Return on equity −35.9% · Return on assets (EBIT) −8.8% · Operating margin −7.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).
What moves the price
The share trades near its 52-week high and 172% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −85%, DOCM screens richer than that median.
Fair Value models
Bear CHF 1.02Fair Value CHF 1.65Bull CHF 2.08
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+10.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.3%
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−8.0% (2020) → −7.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 59 stocks
Beats the industry median on 1/10 measures
Overall it trails its industry peers.
Valuation
Quality Score31 · Bottom 25%
Fair Value upside−85% · Bottom 25%
Profitability
Return on assets−8% · Bottom 25%
Net margin (TTM)−12% · Bottom 25%
Operating margin (TTM)−8% · Bottom 25%
Growth and dividend
Revenue growth12% · Above median
Dividend yield (TTM)2.2% · Below median
Balance sheet
Debt / equity0.61× · Highest 25%
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
P/B1.58× · Pricier than median
P/S (TTM)0.57× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 27
FUTURE (revenue growth)60· sector 23
PAST (return on equity)0· sector 15
HEALTH (low debt)70· sector 98
DIVIDEND (yield)0· sector 67
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "DocMorris AG Fair Value". https://www.fairvalue-calculator.com/stock/DOCM
Frequently asked questions
Is DocMorris AG (DOCM) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of CHF 1.65 versus a price of CHF 10.68, about −85% upside (overvalued).
What is the fair value of DOCM?
Our model-based fair value for DocMorris AG is CHF 1.65 (as of Sep 13, 2026), built from audited fundamentals. The current price: CHF 10.68.
What is the quality score of DOCM?
DocMorris AG has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DocMorris AG (DOCM)?
Our model-based price target is the fair value of CHF 1.65 (as of Sep 13, 2026) from 3 valuation models. Cautious scenario CHF 1.02, optimistic scenario CHF 2.08. It is a calculation from audited fundamentals, not an analyst target.
What is the DocMorris AG stock forecast for 2026?
Our models put fair value at CHF 1.65, about −85% upside versus a price of CHF 10.68 (overvalued). Cautious scenario CHF 1.02, optimistic scenario CHF 2.08. The calculation is refreshed regularly with new filings.
What is the revenue of DocMorris AG (DOCM)?
DocMorris AG reported trailing-twelve-month revenue of about CHF 1.1B (latest available figure, as of Sep 13, 2026).
Does DocMorris AG pay a dividend?
DocMorris AG currently shows a dividend yield of about 2.22% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of DocMorris AG (DOCM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DocMorris AG it is CHF 1.65 per share (as of Sep 13, 2026), against a price of CHF 10.68. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is DocMorris AG stock overvalued or undervalued in 2026?
As of Sep 13, 2026, DOCM trades above its calculated fair value: price CHF 10.68, fair value CHF 1.65, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DOCM?
No. The price is what the market pays today (CHF 10.68); the fair value is what the company's own numbers justify (CHF 1.65). For DocMorris AG the two are CHF 9.03 per share apart. That gap is exactly why we show both numbers side by side.
How much is DocMorris AG worth?
The market values DocMorris AG at about CHF 551M (market capitalisation, as of Sep 13, 2026). Per share that is CHF 10.68; our models calculate a fair value of CHF 1.65 per share.
What do the bullish and bearish scenarios say about DOCM?
Our models span a range for DocMorris AG: cautious scenario CHF 1.02, base CHF 1.65, optimistic CHF 2.08 per share (as of Sep 13, 2026, price CHF 10.68). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of DocMorris AG (DOCM)?
Balance-sheet figures for DocMorris AG (as of Sep 13, 2026): return on equity −35.9%, debt of 0.61 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is DOCM from its 52-week high?
DocMorris AG trades at CHF 10.68, about 18% below its 52-week high of CHF 9.06 and 172% above the low of CHF 3.92 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 1.65 is for.
Which stocks are comparable to DocMorris AG?
From the same area (Healthcare) we also value Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, MedPlus Health Services Limited, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DocMorris AG stock attractive at the current price?
The data as of Sep 13, 2026: price CHF 10.68, calculated fair value CHF 1.65 (−85%), Quality Score 29/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DOCM calculated?
We run DocMorris AG through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of CHF 1.65, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.0 % above its aggregate fair value. DocMorris AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DocMorris AG (DOCM)?
The closing price on Sep 18, 2026 was CHF 10.68. Our model-based fair value is CHF 1.65, about −85% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DocMorris AG right now?
The price sits above even our optimistic bull case (CHF 2.08). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (CHF 1.02 to CHF 2.08) leaves room in how you read the outcome.
Key figures of DocMorris AG
How large is the market capitalisation of DocMorris AG (DOCM)?
The market capitalisation of DocMorris AG is CHF 551M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DocMorris AG (DOCM)?
The price-to-sales ratio of DocMorris AG is 0.30 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DocMorris AG (DOCM)?
Earnings per share at DocMorris AG are CHF −4.58. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of DocMorris AG (DOCM)?
The dividend yield of DocMorris AG is 2.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DocMorris AG (DOCM)?
The net margin of DocMorris AG is −12.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DocMorris AG (DOCM)?
The return on equity (ROE) of DocMorris AG is −35.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DocMorris AG (DOCM)?
On an EBIT basis the return on assets of DocMorris AG is −8.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DocMorris AG (DOCM)?
The operating margin of DocMorris AG is −7.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DocMorris AG (DOCM)?
Revenue at DocMorris AG is growing +11.9% versus a year earlier (3y avg +6.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does DocMorris AG (DOCM) generate?
The free cash flow of DocMorris AG is −CHF 90.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does DocMorris AG (DOCM) carry?
The net debt of DocMorris AG is CHF 169M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch DocMorris AG in the live analysis
One click puts DocMorris AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
